Menu Search
Equities

Scinai Immunotherapeutics Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
2F5:FRA

Scinai Immunotherapeutics Ltd

Actions
  • Price (EUR)0.61
  • Today's Change-0.045 / -6.87%
  • Shares traded1.00
  • 1 Year change-80.07%
  • Beta1.9174
Data delayed at least 15 minutes, as of Feb 13 2026 14:25 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

  • Revenue in USD (TTM)1.15m
  • Net income in USD4.09m
  • Incorporated2003
  • Employees31.00
  • Location
    Scinai Immunotherapeutics LtdJerusalem Biopark2Nd Floor, Hadassah Ein Kerem CampusJERUSALEM 00000IsraelISR
  • Phone+972 89302529
  • Fax+972 89302531
  • Websitehttps://www.scinai.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		2F5:FRA since
announced		Transaction
value
PinCell SrlDeal completed27 Mar 202527 Mar 2025Deal completed-79.25%--
Data delayed at least 15 minutes, as of Feb 13 2026 14:25 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.